title: Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
authors.affiliation: Department of Oncology, Shanghai Sixth People's Hospital of Shanghai Jiaotong University, Shanghai 200233, China. yangyao_6@hotmail.com
authors.forename: Yang
authors.initials: Y
authors.lastname: Yao
authors.forename: Yuan-jue
authors.initials: YJ
authors.lastname: Sun
authors.forename: Hui
authors.initials: H
authors.lastname: Zhao
authors.forename: Yue-wu
authors.initials: YW
authors.lastname: Guo
authors.forename: Feng
authors.initials: F
authors.lastname: Lin
authors.forename: Xun
authors.initials: X
authors.lastname: Cai
authors.forename: Xiao-chun
authors.initials: XC
authors.lastname: Tang
authors.forename: Li-na
authors.initials: LN
authors.lastname: Tang
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D000077150:Oxaliplatin; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C028098:10-hydroxycamptothecin; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin